Richard S P Huang

List of Publications by Year
in descending order

51 papers	437 citations	840776 11 h-index	839539 18 g-index
51 all docs	51 docs citations	51 times ranked	402 citing authors

#	Article	IF	Citations
1	Genomic landscape of nonâ€smallâ€cell lung cancer with methylthioadenosine phosphorylase (<scp>MTAP</scp>) deficiency. Cancer Medicine, 2023, 12, 1157-1166.	2.8	5
2	Predictive Genomic Biomarkers of Hormonal Therapy Versus Chemotherapy Benefit in Metastatic Castration-resistant Prostate Cancer. European Urology, 2022, 81, 37-47.	1.9	16
3	Genomic classification of clinically advanced pancreatic ductal adenocarcinoma (PDAC) based on methylthioadenosine phosphorylase (MTAP) genomic loss (MTAP loss).. Journal of Clinical Oncology, 2022, 40, 604-604.	1.6	1
4	Association of RB1 mutational status with overall genomic landscape in neuroendocrine prostate cancer (NEPC).. Journal of Clinical Oncology, 2022, 40, 156-156.	1.6	0
5	Tumor mutational burden as a predictive biomarker for immune checkpoint inhibitor versus taxane chemotherapy benefit in metastatic castration-resistant prostate cancer: A real-world biomarker study.. Journal of Clinical Oncology, 2022, 40, 162-162.	1.6	0
6	Impact of PD-L1 expression on conventional urothelial bladder carcinoma (UBC) genomic alteration (GA) profile.. Journal of Clinical Oncology, 2022, 40, 563-563.	1.6	0
7	Genomic classification of clinically advanced major genito-urinary cancers (GUca) based on methylthioadenosine phosphorylase (MTAP) genomic loss.. Journal of Clinical Oncology, 2022, 40, 164-164.	1.6	0
8	Tumor mutational burden as a predictive biomarker for immune checkpoint inhibitor versus chemotherapy benefit in first-line metastatic urothelial carcinoma: A real-world study.. Journal of Clinical Oncology, 2022, 40, 547-547.	1.6	4
9	Comprehensive genomic profiling (CGP) of chromophobe renal cell carcinoma (chrRCC) compared with clear cell RCC (ccRCC): Impact of FLCN genomic alteration (GA) status.. Journal of Clinical Oncology, 2022, 40, 292-292.	1.6	0
10	Abstract PD4-09: Comprehensive assessment of the genomic landscape of breast cancer brain metastases reveals targetable alterations and genomic signatures relevant to immune-checkpoint and PARP inhibitors. Cancer Research, 2022, 82, PD4-09-PD4-09.	0.9	0
11	Genomic evolution from hormonal therapies and suitability of prostate cancer diagnostic specimens for metastatic prostate cancer (mPC) genomic stratification.. Journal of Clinical Oncology, 2022, 40, 143-143.	1.6	2
12	Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy by Tumor Mutational Burden in Metastatic Castration-Resistant Prostate Cancer. JAMA Network Open, 2022, 5, e225394.	5.9	37
13	Clinical and pathological features associated with circulating tumor DNA content in realâ€world patients with metastatic prostate cancer. Prostate, 2022, 82, 867-875.	2.3	10
14	OUP accepted manuscript. Oncologist, 2022, , .	3.7	1
15	Association of CD274 (PD-L1) Copy Number Changes with Immune Checkpoint Inhibitor Clinical Benefit in Non-Squamous Non-Small Cell Lung Cancer. Oncologist, 2022, 27, 732-739.	3.7	5
16	Clinicopathologic and Genomic Landscape of Non-Small Cell Lung Cancer Brain Metastases. Oncologist, 2022, 27, 839-848.	3.7	18
17	Clustered 8-Oxo-Guanine Mutations and Oncogenic Gene Fusions in Microsatellite-Unstable Colorectal Cancer. JCO Precision Oncology, 2022, 6, e2100477.	3.0	2
18	The mutational profile of ER-, PR+, HER2- metastatic breast cancer.. Journal of Clinical Oncology, 2022, 40, 1025-1025.	1.6	0

#	Article	IF	Citations
19	Molecular characteristics of advanced colorectal cancer and multi-hit PIK3CA mutations.. Journal of Clinical Oncology, 2022, 40, 3535-3535.	1.6	1
20	Landscape of fibroblast growth factor receptor (FGFR) genomic alterations (GA) in urothelial bladder cancer (UBC).. Journal of Clinical Oncology, 2022, 40, 4568-4568.	1.6	2
21	Comprehensive genomic profiling (CGP) of chromophobe renal cell carcinoma (chrRCC) compared with non-chromophobe RCC (nonchrRCC): Impact of FLCN genomic alteration (GA) status.. Journal of Clinical Oncology, 2022, 40, 4550-4550.	1.6	0
22	Targetable genomic mutations in young women with advanced breast cancer.. Journal of Clinical Oncology, 2022, 40, 1027-1027.	1.6	0
23	Distinct mutational landscapes characterize melanomas metastatic to different anatomical sites.. Journal of Clinical Oncology, 2022, 40, 9562-9562.	1.6	0
24	Pan-cancer landscape of CD274 (PD-L1) and PDCD1LG2 (PD-L2) structural variations.. Journal of Clinical Oncology, 2022, 40, 3133-3133.	1.6	0
25	Impact of PD-L1 expression on conventional urothelial bladder carcinoma (UCB) genomic alteration (GA) profile.. Journal of Clinical Oncology, 2022, 40, e16535-e16535.	1.6	0
26	Genomic Biomarkers and Genome-Wide Loss-of-Heterozygosity Scores in Metastatic Prostate Cancer Following Progression on Androgen-Targeting Therapies. JCO Precision Oncology, 2022, , .	3.0	10
27	Clinicopathologic, genomic and protein expression characterization of 356 <scp>ROS1</scp> fusion driven solid tumors cases. International Journal of Cancer, 2021, 148, 1778-1788.	5.1	14
28	Predictive Biomarkers for Immune Checkpoint Inhibitors in Metastatic Breast Cancer. Cancer Medicine, 2021, 10, 53-61.	2.8	39
29	A pan-cancer analysis of PD-L1 immunohistochemistry and gene amplification, tumor mutation burden and microsatellite instability in 48,782 cases. Modern Pathology, 2021, 34, 252-263.	5.5	78
30	Correlating ROS1 Protein Expression With ROS1 Fusions, Amplifications, and Mutations. JTO Clinical and Research Reports, 2021, 2, 100100.	1.1	8
31	Clinicopathologic and genomic characterization of PD-L1-positive uterine cervical carcinoma. Modern Pathology, 2021, 34, 1425-1433.	5.5	19
32	Landscape of Biomarkers in Non-small Cell Lung Cancer Using Comprehensive Genomic Profiling and PD-L1 Immunohistochemistry. Pathology and Oncology Research, 2021, 27, 592997.	1.9	11
33	Clinicopathologic and Genomic Characterization of PD-L1 Positive Urothelial Carcinomas. Oncologist, 2021, 26, 375-382.	3.7	8
34	Plasma circulating tumor DNA (ctDNA) fraction and real-world overall survival (rwOS) in metastatic castration resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2021, 39, e17035-e17035.	1.6	0
35	Genomic landscape of MSH6-mutated clinically advanced castrate-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2021, 39, 5062-5062.	1.6	1
36	Pan-cancer landscape of CD274 (PD-L1) copy number changes in 244 584 patient samples and the correlation with PD-L1 protein expression. , 2021, 9, e002680.		13

#	Article	IF	Citations
37	Genomic landscape of non-small cell lung cancer (NSCLC) with methylthioadenosine phosphorylase (MTAP) deletion.. Journal of Clinical Oncology, 2021, 39, 9116-9116.	1.6	0
38	Clinically advanced pelvic squamous cell carcinomas (pSCC) in men and women: A comprehensive genomic profiling (CGP) study.. Journal of Clinical Oncology, 2021, 39, 3130-3130.	1.6	1
39	Molecular, immunologic, and clinicodemographic landscape of MYC-amplified (MYCamp) advanced prostate cancer (PCa).. Journal of Clinical Oncology, 2021, 39, 5041-5041.	1.6	0
40	Comprehensive molecular profiling of pleural mesothelioma according to histologic subtype.. Journal of Clinical Oncology, 2021, 39, 8555-8555.	1.6	0
41	Pan-cancer analysis of CD274 (PD-L1) mutations in 314,631 patient samples and subset correlation with PD-L1 protein expression.. Journal of Clinical Oncology, 2021, 39, 2605-2605.	1.6	0
42	Clinicopathologic and Genomic Landscape of Breast Carcinoma Brain Metastases. Oncologist, 2021, 26, 835-844.	3.7	16
43	Pan-cancer analysis of CD274 (PD-L1) mutations in 314,631 patient samples and subset correlation with PD-L1 protein expression. , 2021, 9, e002558.		7
44	Clinically Advanced Pheochromocytomas and Paragangliomas: A Comprehensive Genomic Profiling Study. Cancers, 2021, 13, 3312.	3.7	9
45	Contrasting genomic profiles from metastatic sites, primary tumors, and liquid biopsies of advanced prostate cancer. Cancer, 2021, 127, 4557-4564.	4.1	5
46	Circulating Cell-Free DNA Yield and Circulating-Tumor DNA Quantity from Liquid Biopsies of 12â€‰139 Cancer Patients. Clinical Chemistry, 2021, 67, 1554-1566.	3.2	13
47	Pan-cancer landscape of CD274 (PD-L1) rearrangements in 283,050 patient samples, its correlation with PD-L1 protein expression, and immunotherapy response. , 2021, 9, e003550.		8
48	Treatment of Pediatric Glioblastoma with Combination Olaparib and Temozolomide Demonstrates 2-Year Durable Response. Oncologist, 2020, 25, e198-e202.	3.7	11
49	Identification and Utilization of Biomarkers to Predict Response to Immune Checkpoint Inhibitors. AAPS Journal, 2020, 22, 132.	4.4	27
50	Biomarkers in Breast Cancer: An Integrated Analysis of Comprehensive Genomic Profiling and PD-L1 Immunohistochemistry Biomarkers in 312 Patients with Breast Cancer. Oncologist, 2020, 25, 943-953.	3.7	19
51	Genomic Profiling of Circulating Tumor DNA From Cerebrospinal Fluid to Guide Clinical Decision Making for Patients With Primary and Metastatic Brain Tumors. Frontiers in Neurology, 2020, 11, 544680.	2.4	16